The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Alpha-synuclein Seed Amplification Assay Program, 2021Detection of Single Molecules of Alpha-synuclein in Extracellular Vesicles
Study Rationale: The pathological changes observed in the brain tissue of people with Parkinson’s disease (PD) compared to healthy individuals motivated researchers to explore alpha-synuclein as a...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Evaluation of “PDRepair,” a Novel Neuroprotective and Neurorestorative Therapeutic for GBA1-associated Parkinson’s Disease
Study Rationale: Mutations in the GBA1 gene, which encodes an enzyme called GCase, is the strongest genetic risk factor for Parkinson’s Disease (PD) and most often results in the production of GCase...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Preclinical Efficacy and Biomarker Development for a Clinical Stage Inhibitor of Lipid Metabolism in Parkinson’s Disease
Study Rationale: A hallmark characteristic of Parkinson’s disease (PD) is the accumulation of alpha-synuclein, a small lipid-binding protein involved in transporting lipids and proteins throughout the...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Establishing the Therapeutic Potential of Engineered Neural Circuits in a Preclinical Model of Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is caused by the death of specific brain cells that connect two different regions of the brain, disrupting a neural circuit that is key for motor function. We...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Preclinical Screening of Compounds that Modulate the Pathological Interplay between Alpha-synuclein and Synapsin III for the Treatment of Parkinson’s Disease
Study Rationale: The protein alpha-synuclein forms abnormal aggregates in the brains of people with Parkinson's disease (PD). Although the mechanism by which this aggregation leads to the pathological...
-
Fall 2021 RFP: Outcome Measures, 2021Characterization of Sterols in CSF and Plasma as a Possible Biomarker for Parkinson’s Disease
Study Rationale: Sterols, including cholesterol, are very abundant in the brain, where they form important components of cell membranes and act as signaling molecules within and between cells...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.